Prolacta Bioscience, Inc. Completes Series E Preferred Stock Financing

Prolacta Bioscience, Inc.

Represented Prolacta Bioscience, Inc. with its closing of a $35 million Series E Preferred Stock financing. The investors include two Essex Woodlands Funds, Aisling Capital IV, L.P. and Health Evolution Partners Fund I, L.P., all of which focus on investing in products, technologies and global businesses in the healthcare industry.

Prolacta Bioscience is a privately held life sciences company dedicated to improving the quality of life in the most fragile infants through the creation and sale of specialty formulations made from human milk for the nutritional needs of premature infants in neonatal intensive care units.

The Newport Beach-based team representing Prolacta included Mark SkaistRyan Wilkins and Sonya Attal.